- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03047863
Therapeutic Effect of EGF Cream for Cutaneous Adverse Event of EGFR Inhibitors
The Therapeutic Effect of Topical EGF Cream for Dermatologic Adverse Events Related to EGFR Inhibitors
Study Overview
Status
Intervention / Treatment
Detailed Description
Epidermal growth factor receptor(EGFR) is involved in cell proliferation and is overexpressed or abnormally activated in malignant tumors originating from the colon, breast, ovary, pancreas, and lung. EGFR tyrosine kinase inhibitor(TKI), gefitinib, erlotinib, and afatinib have been for the treatment of cancer associated with EGFR gene mutation. In addition, monoclonal antibodies to EGFR, such as cetuximab and panitumumab, have been used as a chemotherapy for rectal cancer without ras gene mutation and advanced head and neck cancer.
The incidence of cutaneous toxicity of EGFR inhibitors is reported to be 75-80%. Clinical features include acneform folliculitis, xerosis, paronychia, and itching. Of these, about 10% of patients with Grade 3 or greater have a detrimental effect on quality of life and adherence to treatment, resulting in impaired therapeutic results.
There have been many attempts to prevent or treat such skin toxicity. However, there has been no scientifically proven treatment until now.
There is a growing interest in the role of EGF emulsifiers in the treatment of skin adverse effects of EGFR inhibitors, as a result of studies that improve acne significantly compared to placebo.
The purpose of this study is to evaluate the therapeutic efficacy of EGF cream in the treatment of skin adverse effects in patients with malignant tumors treated with EGFR inhibitor (TKI or monoclonal antibody).
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Gyeonggi-do
-
Suwon, Gyeonggi-do, Korea, Republic of, 16247
- Recruiting
- St. Vincent's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients who received EGFR inhibitors (gefitinib, erlotinib, afatinib, cetuximab, etc.) for malignant tumors
- Patients with EGFR inhibitor-associated skin reactions: National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE V4.03) Grade 2, 3 Patients
- Patients who can understand and follow the protocol
- Patients who spontaneously agreed to the study
Exclusion Criteria:
- NCI-CTCAE grade 4 patients requiring systemic drug therapy
- Those with a history of antibiotic treatment, local and systemic steroid therapy within 4 weeks for reasons other than EGFR inhibitors
- Patients with existing acne history
- Patients who have already received anti-EGFR therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Repair Control EGF®
EGF cream was applied.
Half of face was treated with emollient containing EGF.
|
A Split face study was done. Patients applied 1 finger tip unit of EGF cream on one side of face, twice a day for 4 weeks. EGF cream(Repair Control EGF®) containing 10 ppm of rhEGF was prepared at D.N. Co., Ltd. (Seoul, South Korea)
Other Names:
|
Placebo Comparator: Cream without rhEGF
Placebo cream without EGF was applied.
The other half of face was treated with only emollient which was not containing EGF.
|
A Split face study was done. Patients applied 1 finger tip unit of cream on the other side of face, twice a day for 4 weeks. Placebo cream was prepared at at D.N. Co., Ltd. (Seoul, South Korea), consisted of same ingredient with EGF cream except rhEGF |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The change of severity of acneform eruption induced by EGFR inhibitors
Time Frame: Baseline, 1 week, 2 weeks, 4 weeks
|
To evaluate the severity of acneiform eruption, the investigators take a photograph of full face.
The number of inflammatory and noninflammatory lesions will be counted and accessed the severity based on the Korean Acne Grading System(KAGS).
|
Baseline, 1 week, 2 weeks, 4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change of skin hydration
Time Frame: Baseline, 1 week, 2 weeks, 4 weeks
|
Skin hydration is measured with Corneometer® (CM820/825; C-K Electronics, Cologne, Germany). It shows the skin moisturizing condition in arbitrary units(AU) and the unit is from 0 to 220. |
Baseline, 1 week, 2 weeks, 4 weeks
|
change of sebum production
Time Frame: Baseline, 1 week, 2 weeks, 4 weeks
|
Sebum production is measured with Sebumeter® (SM815; C-K Electronics, Cologne, Germany). It measured at forehead, cheek and chin, presented as ㎍/㎠. |
Baseline, 1 week, 2 weeks, 4 weeks
|
Investigator's global assessment score
Time Frame: Baseline, 1 week, 2 weeks, 4 weeks
|
Investigator's global assessment (IGA) Score : It will be assessed as a 5-point scale (-1 = worsen, to 3 = marked improvement).
|
Baseline, 1 week, 2 weeks, 4 weeks
|
Patient's global assessment score
Time Frame: Baseline, 1 week, 2 weeks, 4 weeks
|
Patient's global assessment (PGA) score will be assessed as a 5-point scale (-1 = worsen, to 3 =marked improvement).
|
Baseline, 1 week, 2 weeks, 4 weeks
|
The side effects of product
Time Frame: Baseline, 1 week, 2 weeks, 4 weeks
|
It will be assessed by patient-report.
|
Baseline, 1 week, 2 weeks, 4 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Jung Min Bae, MD, PhD, The Catholic University of Korea
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VC16EISI0179
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug-Related Side Effects and Adverse Reactions
-
Texas A&M UniversityInnovativeGx; Texas A&M Health Family Care Clinic; iC42 Clinical Research and... and other collaboratorsRecruiting
-
Leiden University Medical Centerbio.logis digital health GmbHRecruiting
-
Fayoum UniversityCompletedAdverse Drug ReactionEgypt
-
CHU de ReimsCompletedChild With Adverse Drug Reactions
-
Companion Dx Reference Lab, LLCUnknownDrug Side Effects
-
CHU de ReimsCompleted
-
Germans Trias i Pujol HospitalCompletedAdverse Drug Reaction
-
University College CorkCompletedAdverse Drug ReactionIreland
-
University College CorkCompleted
-
Universidade Estadual Paulista Júlio de Mesquita...CompletedAdverse Drug ReactionBrazil
Clinical Trials on Repair Control EGF®
-
The Catholic University of KoreaUnknownDrug-Related Side Effects and Adverse Reactions | Epidermal Growth FactorKorea, Republic of
-
SVS Institute of Dental SciencesUnknown
-
Medtronic CardiovascularCompletedTricuspid Valve Regurgitation | Tricuspid Valve InsufficiencyUnited States
-
Henry Ford Health SystemRecruitingGraft Versus Host DiseaseUnited States
-
San Bonifacio HospitalCompletedIndirect Inguinal Hernia | Direct Inguinal HerniaItaly
-
CONMED CorporationRecruitingRotator Cuff TearsUnited States
-
Women and Infants Hospital of Rhode IslandCompleted
-
Shanghai NewMed Medical Co., Ltd.Recruiting
-
University of CalgaryAcumed, LLCNot yet recruitingScapholunate Dissociation | Complete Tear of Scapholunate Ligament
-
Cordis CorporationQuintiles, Inc.; HealthCore-NERICompletedAbdominal Aortic AneurysmUnited States, Japan